IMCC logo
IM Cannabis Corp.(IMCC)
$2.84—Stale · unknown old
9/28/26

IM Cannabis (IMCC)

Monday
7:39 AM
ThesisRecent strategic partnerships and product launches are expected to enhance revenue growth and improve market sentiment towards IM Cannabis.

Revenue Outlook

★ Analysts see FY2026 revenue reaching $63M — +14.7% growth in a single year.

The Bull Case for Growth

  1. 01IM Cannabis has secured a new distribution agreement with a major European pharmacy chain, potentially increasing market access by 30%.
  2. 02The company is in the process of launching a new line of CBD-infused wellness products, expected to capture a growing segment of the consumer market.
  3. 03Recent changes in Canadian cannabis regulations are expected to favor larger producers, potentially improving IM Cannabis's competitive position.
  4. 04The company reported a 40.8% increase in EPS, indicating a potential turnaround in profitability despite ongoing operational challenges.
  5. 05Growing acceptance of cannabis for medical use
  6. 06Expansion of the European cannabis market
  7. 07Changes in regulatory frameworks affecting cannabis sales in Canada and Europe
  8. 08Market share growth in the medical cannabis segment
FY2025 Snapshot
EPS
$-80.10
1Y Return
-94.9%

IMCC Chart

0.75.610.515.420.32.84IMCC Daily2.84May '26Jun '26Aug '26Sep '26

My Notes

  • "We are committed to expanding our market presence and product offerings to meet the growing demand for medical cannabis."
  • Moat: IM Cannabis's proprietary cultivation techniques and established distribution channels provide a moderate level of competitive advantage.
  • growth - Investors looking for exposure to the expanding cannabis market and potential for high returns.
  • Higher interest rates could increase financing costs for expansion and operational needs…
  • Watch on earnings: Canadian medical cannabis market growth rate, Average selling price per gram of cannabis, Regulatory changes in key markets.

One Sentence Summary:

The bull case: IM Cannabis is positioned for +14.7% growth on the back of im cannabis has secured a new distribution agreement with a major european pharmacy chain.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.